Drug intelligence / Profile preview

A-3

Development stage: Preclinical
Modality: Small Molecules

Overview

A-3 is a novel small molecule synthesized as a derivative of apocynin and tandospirone. It has demonstrated antioxidant properties by decreasing reactive oxygen species (ROS) concentrations in vitro and reversing decreases in glutathione levels in the medial prefrontal cortex of rats. Furthermore, A-3 exhibits anti-dopaminergic effects, as evidenced by its ability to ameliorate methamphetamine-induced hyperlocomotion in an animal model of schizophrenia, suggesting potential for alleviating psychotic symptoms.

Targets

DRD (Dopamine receptors)GSH (Glutathione)

Beyond the preview

Go deeper on A-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A-3.

Explore the full profile